Literature DB >> 31592839

Innate immunity in ischemia-reperfusion injury and graft rejection.

Kojiro Nakamura1,2,3, Shoichi Kageyama1, Jerzy W Kupiec-Weglinski1.   

Abstract

PURPOSE OF REVIEW: Although organ transplantation has become the standard life-saving strategy for patients with end-stage organ failure and those with malignancies, effective and safe therapeutic strategies to combat allograft loss remain to be established. With the emerging evidence suggesting the critical role of innate immunity in the mechanism of allograft injury, we summarize the latest understanding of macrophage-neutrophil cross-communication and discuss therapeutic prospects of their targeting in transplant recipients. RECENT
FINDINGS: Macrophages and neutrophils contribute to the pathogenesis of early peritransplant ischemia-reperfusion injury and subsequent allograft rejection immune cascade, primarily by exacerbating inflammatory response and tissue damage. Noteworthy, recent advances enabled to elucidate multifaceted functions of innate immune cells, which are not only deleterious but may also prove graft-protective. Indeed, the efficacy of macrophage polarizing regimens or macrophage-targeted migration have been recognized to create graft-protective local environment. Moreover, novel molecular mechanisms in the neutrophil function have been identified, such as neutrophil extracellular traps, tissue-repairing capability, crosstalk with macrophages and T cells as well as reverse migration into the circulation.
SUMMARY: As efficient strategies to manage allograft rejection and improve transplant outcomes are lacking, newly discovered, and therapeutically attractive innate immune cell functions warrant comprehensive preclinical and clinical attention.

Entities:  

Year:  2019        PMID: 31592839     DOI: 10.1097/MOT.0000000000000709

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  6 in total

Review 1.  Hemorheological and Microcirculatory Factors in Liver Ischemia-Reperfusion Injury-An Update on Pathophysiology, Molecular Mechanisms and Protective Strategies.

Authors:  Norbert Nemeth; Katalin Peto; Zsuzsanna Magyar; Zoltan Klarik; Gabor Varga; Mihai Oltean; Anna Mantas; Zoltan Czigany; Rene H Tolba
Journal:  Int J Mol Sci       Date:  2021-02-13       Impact factor: 5.923

2.  Pre-Transplant Expression of CCR-2 in Kidney Transplant Recipients Is Associated With the Development of Delayed Graft Function.

Authors:  Paola Pontrelli; Simona Simone; Federica Rascio; Francesco Pesce; Francesca Conserva; Barbara Infante; Giuseppe Castellano; Fabio Sallustio; Marco Fiorentino; Gianluigi Zaza; Anna Gallone; Michele Battaglia; Pasquale Ditonno; Giovanni Stallone; Loreto Gesualdo; Giuseppe Grandaliano
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

Review 3.  Targeting inflammation and immune activation to improve CTLA4-Ig-based modulation of transplant rejection.

Authors:  Marcos Iglesias; Daniel C Brennan; Christian P Larsen; Giorgio Raimondi
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 4.  Improving the ischemia-reperfusion injury in vascularized composite allotransplantation: Clinical experience and experimental implications.

Authors:  Jiqiang He; Umar Zeb Khan; Liming Qing; Panfeng Wu; Juyu Tang
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

5.  Creatine Supply Attenuates Ischemia-Reperfusion Injury in Lung Transplantation in Rats.

Authors:  Francine M Almeida; Angela S Battochio; João P Napoli; Katiusa A Alves; Grace S Balbin; Manoel Oliveira-Junior; Henrique T Moriya; Paulo M Pego-Fernandes; Rodolfo P Vieira; Rogerio Pazetti
Journal:  Nutrients       Date:  2020-09-10       Impact factor: 5.717

Review 6.  Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices.

Authors:  Gennaro Martucci; Federico Pappalardo; Harikesh Subramanian; Giulia Ingoglia; Elena Conoscenti; Antonio Arcadipane
Journal:  Nutrients       Date:  2021-03-05       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.